<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783276</url>
  </required_header>
  <id_info>
    <org_study_id>DA009262-14</org_study_id>
    <secondary_id>P50DA009262</secondary_id>
    <secondary_id>DPMCDA</secondary_id>
    <nct_id>NCT00783276</nct_id>
  </id_info>
  <brief_title>An fMRI Study of SYN115 in Cocaine Dependent Subjects</brief_title>
  <official_title>An fMRI Study of SYN115 in Cocaine Dependent Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The dopamine system is critical in modulation of reward and has been implicated in the
      initiation and maintenance of addiction (Volkow et al 2004). Medications that increase
      dopamine either directly or indirectly have been shown to have preliminary efficacy at
      reducing cocaine use in cocaine dependent subjects (Grabowski et al 2004a; Schmitz et al
      2008). A novel class of medications that has recently been shown to indirectly modulate
      dopamine function is adenosine A2A receptor antagonists (Fuxe et al 2007). Based on their
      effect on dopamine function it has been suggested that these compounds may be efficacious in
      the treatment of drug addiction (Ferre et al 2007c). Before clinical efficacy studies are
      undertaken, more basic research on the effects of adenosine A2A antagonists on brain function
      and behavior are warranted. The aim of this study is to examine the acute effects of a single
      dose of the selective adenosine A2A antagonist (SYN115, Synosia Therapeutics, Chemical name:
      4-Hydroxy-4-methyl-piperidine-1-carboxylic
      acid-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide) on brain function and behavior in
      cocaine dependent individuals using functional magnetic resonance imaging (fMRI). To examine
      the effect of a single dose of SYN115 on brain function and behavior in cocaine dependent
      subjects.

      Hypotheses:

        1. SYN115 100 mg will increase brain activation in the dorsolateral prefrontal cortex
           compared to placebo in cocaine dependent subjects performing a working memory task.

        2. SYN115 100 mg will increase brain activation in the ventral striatum compared to placebo
           in cocaine dependent subjects performing a reversal learning task.

        3. SYN115 100 mg will reduce brain activation in the anterior cingulate gyrus and amygdala
           compared to placebo in cocaine dependent subjects performing a cocaine-word Stroop task.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fMRI Brain Activation</measure>
    <time_frame>Minutes</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYN115</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYN115</intervention_name>
    <description>100 mg single dose</description>
    <arm_group_label>SYN115</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>PLACEBO</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA: (1) 13 Male and 13 female subjects age 18 to 50 who currently meet
        DSM-IV criteria for cocaine dependence. (2) At least one cocaine positive urine during
        screening. (3) Female subjects: a negative pregnancy test.

        EXCLUSION CRITERIA: (1) current or past DSM-IV Axis I disorder other than substance
        abuse/dependence (2) any significant non-psychiatric medical illness requiring ongoing
        medical treatment (3) any clinically significant abnormality on EKG (4) hypertension (5)
        cardiovascular disease (6) substance dependence other than cocaine, marijuana, or nicotine
        within the last 3 months. (7) Positive breath alcohol (8) Positive urine drug screen for
        drugs other than cocaine or THC at the time of behavioral testing (9) For female subjects:
        known pregnancy or a positive pregnancy test or current breast feeding (10) Diagnosis of
        Adult Attention Deficit Disorder as determined by: a) meeting DSM-IV criteria for childhood
        ADHD, b) currently has impairing ADHD symptoms, c) ADHD symptoms can not have remitted at
        any period since childhood (11) HIV positive (12) I.Q. below 70 (13) Use of medications
        which affect the central nervous system (CNS) or could interact with SYN115. (13) History
        of pacemaker or metal implants or welding or metal work without protective eyewear.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick G Moeller, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTHSC-Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Moeller FG, Steinberg JL, Lane SD, Kjome KL, Ma L, Ferre S, Schmitz JM, Green CE, Bandak SI, Renshaw PF, Kramer LA, Narayana PA. Increased Orbitofrontal Brain Activation after Administration of a Selective Adenosine A(2A) Antagonist in Cocaine Dependent Subjects. Front Psychiatry. 2012 May 28;3:44. doi: 10.3389/fpsyt.2012.00044. eCollection 2012.</citation>
    <PMID>22654774</PMID>
  </results_reference>
  <results_reference>
    <citation>Lane S, Green C, Steinberg J, Ma L, Schmitz J, Rathnayaka N, Bandak S, Ferre S, Moeller F. Cardiovascular and Subjective Effects of the Novel Adenosine A(2A) Receptor Antagonist SYN115 in Cocaine Dependent Individuals. J Addict Res Ther. 2012 Mar 28;S1. pii: 009.</citation>
    <PMID>22905331</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Virginia Commonwealth University</investigator_affiliation>
    <investigator_full_name>Frederick Gerard Moeller</investigator_full_name>
    <investigator_title>Professor - Psychiatry, Behavioral Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

